Company Filing History:
Years Active: 2014
Title: Innovator Maria Luisa Dupuis: Pioneering Cancer Diagnostics
Introduction: Maria Luisa Dupuis is an accomplished inventor based in Rome, Italy. She has made significant contributions to the field of cancer research, particularly in developing innovative diagnostic tools. Her work has been instrumental in enhancing our understanding of Ewing sarcoma, a type of bone cancer primarily affecting children and adolescents.
Latest Patents: Maria Luisa Dupuis holds a patent for a single-chain variable fragment (scFv) that is capable of recognizing and binding to the CD99 human protein. This invention relates to a specific epitope present in the extracellular domain of CD99, which is expressed on Ewing sarcoma cells. The unique property of this single-chain variable fragment allows for selective binding, making it a promising tool for the diagnosis and treatment of Ewing sarcoma.
Career Highlights: Maria Luisa Dupuis is associated with the Istituto Ortopedico Rizzoli, where she applies her expertise in cancer research. Her dedication to improving patient outcomes through innovative solutions highlights her commitment to advancing medical science. With one patented invention under her belt, she continues to explore new ideas that can transform cancer diagnostics.
Collaborations: Throughout her career, Maria has worked alongside notable colleagues, including Piero Picci and Katia Scotlandi. These collaborations have fostered an environment of innovation and knowledge sharing, further enhancing the quality of research and development undertaken at the Istituto Ortopedico Rizzoli.
Conclusion: Maria Luisa Dupuis exemplifies the spirit of innovation in the medical field. Her pioneering patent for a single-chain variable fragment that targets CD99 human protein showcases her ability to contribute significantly to cancer diagnostics. As she continues her research, her work will likely play a crucial role in advancing treatment options for Ewing sarcoma and improving patient care.